Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented results from a phase II study evaluating the combination of its pipeline candidates CDX-301 and CDX-1401 in patients with malignant melanoma at the annual meeting of the American Society of Clinical Oncology. The study was conducted by the Cancer Immunotherapy Trials Network under a Cooperative Research and Development Agreement between Celldex and the Cancer Therapy Evaluation Program of the National Cancer Institute.
Results from the study showed that the combination of CDX-1401 and CDX-301 generated significant NY-ESO-1 specific T cell responses in patients with melanoma. On the safety front, both combination regimens were found to be well tolerated with no drug-related adverse events being reported that required discontinuation of treatment.
Given the encouraging phase II study results, Celldex announced the initiation of a targeted study in patients with NY-ESO-1 positive disease to evaluate whether these enhanced immune responses can lead to improved clinical outcomes.
Currently, prescribed treatments for melanoma include drugs like Opdivo and Yervoy.
Apart from CDX-301 and CDX-1401, other candidates in Celldex’s pipeline include glembatumumab vedotin (phase II studies for triple negative breast cancer and metastatic melanoma), varlilumab (phase I/II, several combination studies across multiple types of cancer) and CDX-014 (phase I, renal cell carcinoma).
Celldex is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) and Retrophin, Inc. (NASDAQ:RTRX) – both sporting a Zacks Rank #1 (Strong Buy) and Acorda Therapeutics, Inc. (NASDAQ:ACOR) – carrying a Zacks Rank #2 (Buy).
ACORDA THERAPT (ACOR): Free Stock Analysis Report
CELLDEX THERAPT (CLDX): Free Stock Analysis Report
RETROPHIN INC (RTRX): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
Original post
Zacks Investment Research